- $488.07m
- $320.48m
- $10.84m
Brief: Crescent Biopharma Announces FDA Clearance Of Ind Application For CR-002, A Pd-L1-Targeted Topoisomerase Inhibitor Adc, For The Treatment Of Solid Tumors
Crescent Biopharma posts smaller-than-expected Q2 net loss
U.S. STOCKS ON THE MOVE-Cintas, Veradermics
Crescent Biopharma slips on $125 mln share offering
Brief: Crescent Biopharma Inc Prices Its Underwritten Public Offering Of 8,094,793 Ordinary Shares At $14.50 Per Share
Crescent Biopharma dips on planned equity raise
Brief: Crescent Biopharma - May Offer And Sell Up To $500 Million Of Securities - SEC Filing
Crescent Biopharma Q1 net loss widens on R&D expenses
Crescent Biopharma rises as global trial for new cancer drug starts
Brief: Crescent Biopharma Announces First Patient Dosed In Ascend Phase 1/2 Clinical Trial Of CR-001
U.S. STOCKS ON THE MOVE-Oklo, AMD, Lam Research
U.S. STOCKS ON THE MOVE-Aligos, Intel, Travelers Companies
U.S. STOCKS ON THE MOVE-Teledyne, Arm Holdings, Nathan’s Famous
U.S. STOCKS ON THE MOVE-United Airlines, TE Connectivity, Halliburton
Guggenheim initiates coverage on Crescent Biopharma with 'buy'
U.S. STOCKS ON THE MOVE-Raymond James, CAVA, Paramount Skydance
U.S. STOCKS ON THE MOVE-Meta, GE Vernova, Kroger
Brief: Kelun-Biotech And Crescent Biopharma Announce Strategic Partnership
Crescent Biopharma jumps after cancer drug partnership